adenovirus/Semliki Forest virus hybrid vector delivered IL-12 immunotherapy (Digna Biotech)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameadenovirus/Semliki Forest virus hybrid vector delivered IL-12 immunotherapy (Digna Biotech)
Drug Alias Nameadenovirus/Semliki Forest virus hybrid vector delivered IL-12 immunotherapy (Digna Biotech)
ClassificationBiologics
Mechanisms of ActionInterleukin-12 modulators
TargetsInterleukin-12
Therapy Area/IndicationsNeoplasmsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDigna Biotech Sl
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDigna Biotech Sl
Active IndicationsN/A
Inactive IndicationsNeoplasmsHepatitis B

Other Information

ATC CodeN/A
Related LinksN/A